^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Kaposi Sarcoma
    Drug:pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    POMALYST is a thalidomide analogue indicated, for the treatment of adult patients:…with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pomalidomide has been FDA approved for the treatment of adult patients with AIDS-related KS after failure of highly active ART.